Ocuphire Pharma appoints Joseph Schachle COO; $400K salary, 300K option grant

Opus Genetics, Inc.

Joseph Schachle appointed COO effective Nov 27, 2023; previously COO of Opus Genetics.
Base salary $400K, target annual bonus 45% of base, 300K stock option grant.
Stock option vests 25% on 1-year anniversary, remaining monthly over 36 months.
Appointment part of strategic initiative to advance lead retina asset APX3330 into registrational studies.
Severance: 9 months salary continuation plus COBRA reimbursement if terminated without cause or for good reason.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joseph Schachle

Chief Operating Officer

IRD · Opus Genetics, Inc.

Effective: 2023-11-27
Filed: November 27, 2023, 6:59 PM ET

On November 22, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Joseph Schachle, age 58, as the Company’s Chief Operating Officer, effective as of November 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Schachle was appointed as Chief Operating Officer at Opus Genetics, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On November 22, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Joseph Schachle, age 58, as the Company’s Chief Operating Officer, effective as of November 27, 2023.

View on SEC.gov

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-054632

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.